Avigen Presents At the 37th Annual Meeting of the Society for Neuroscience
04 nov. 2007 15h00 HE
|
Avigen, Inc.
ALAMEDA, Calif., Nov. 4, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapies for the treatment of chronic neurological conditions, today announced the...
Avigen's AV411 Shows Promising Initial Results for Neuropathic Pain
03 nov. 2007 15h30 HE
|
Avigen, Inc.
SALT LAKE CITY, Nov. 3, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced first-in-patient top line data...
Avigen to Present At Upcoming Healthcare Conferences
30 oct. 2007 08h00 HE
|
Avigen, Inc.
ALAMEDA, Calif., Oct. 30, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapies for the treatment of chronic neurological conditions, announced today...
Avigen Reports Third Quarter 2007 Financial Results
24 oct. 2007 08h00 HE
|
Avigen, Inc.
ALAMEDA, Calif., Oct. 24, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapies for the treatment of chronic neurological conditions, today reported...
Avigen to Present At 2007 BIO Investor Forum
03 oct. 2007 08h00 HE
|
Avigen, Inc.
ALAMEDA, Calif., Oct. 3, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company innovating therapeutics for chronic neurological care, announced today that Chief Business...
Avigen to Present At UBS Global Life Sciences Conference
18 sept. 2007 08h00 HE
|
Avigen, Inc.
ALAMEDA, Calif., Sept. 18, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company innovating therapeutics for chronic neurological care, announced today that President and CEO...
Avigen Initiates European Multi-Center AV650 Phase II Spasticity Trial in Patients with Multiple Sclerosis
05 sept. 2007 08h00 HE
|
Avigen, Inc.
ALAMEDA, Calif., Sept. 5, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company innovating therapeutics for the treatment of neurological conditions, today announced the...
Avigen Initiates U.S. Clinical Development for AV411
13 août 2007 08h00 HE
|
Avigen, Inc.
ALAMEDA, Calif., Aug. 13, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of chronic neurological conditions, today...
Avigen Reports Second Quarter 2007 Financial Results
25 juil. 2007 08h00 HE
|
Avigen, Inc.
ALAMEDA, Calif., July 25, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN) a biopharmaceutical company developing innovative therapies for the treatment of chronic neurological conditions, today...
Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
26 juin 2007 12h58 HE
|
Avigen, Inc.
ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for the treatment of neurological conditions, announced today that...